Cholera vaccination drive begins in high-risk districts in Somalia
Somalia has just launched one of Africa’s largest immunization campaigns using oral cholera vaccines (OCV). The campaign, which runs from 22 to 28 June, 2019 in high-risk areas of Somalia, will vaccinate more than 650 000 people aged one year and above to eliminate the risk of the disease among vulnerable populations and to prevent recurring cholera outbreaks in the country.... read more
Death toll from acute encephalitis in Muzaffarpur rises to 129 children
At least 129 children have now died of acute encephalitis syndrome (AES) in Muzaffarpur in Bihar since an outbreak earlier this month, a medical official said on Sunday.
The death toll from AES, a fever that affects the central nervous system, has risen from 97 reported last Monday and medical and government officials are facing mounting criticism for struggling to contain the crisis in the town. The precise causes of AES are not known, though a majority of medical professionals say it is linked to a ferocious heat-wave.... read more
Lower Incidence of Type 1 Diabetes Seen After Complete Rotavirus Vaccine Series
Receipt of the complete rotavirus vaccine series in infancy is associated with a significant reduction in the incidence of type 1 diabetes in childhood, according to a database study.
Researchers noted that among children who received the complete rotavirus vaccination series, the incidence of type 1 diabetes per 100,000 person-years was 12.2 (12.4 for girls, 12.0 for boys),... read more
MMF Stoppage Carries Risk in Systemic Sclerosis
Mycophenolate mofetil (MMF, CellCept) was effective in halting rapidly progressive diffuse cutaneous systemic sclerosis (SSc), but a substantial percentage of patients experienced recurrences when the treatment was stopped, a small open-label study found. Five out of 19 patients (26.3%) who discontinued or decreased the dose of mycophenolate after almost 23 months of treatment had recurrences of the skin manifestations,... read more
FDA Panel Against Cutting PAD Device Access
The late mortality signal of paclitaxel-coated devices used in peripheral artery disease (PAD) shouldn't force these balloons and stents off the market, a panel concluded at an FDA advisory committee meeting.
Citing a totality of evidence that still weighs heavily in favor of benefits from these devices ... read more